Marinus Pharmaceuticals Stock News

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50% and 37.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.'s (NASDAQ: AG

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) Pyrukynd (mitapivat) was approved for the treatment of hemolytic anemia in people with pyruvate kinase deficiency. Hemolysis refers to the destruction of red blood cells. Pyrukynd is a "new molecular entity," a term that refers to a drug containing an active moiety that hasn''t been previously approved by the FDA. NME approval, therefore, is considered a measure of innovation in drug research. Another NME that passed the FDA hurdle was Sanofi''s (NASDAQ: SNY ) Enjaymo for the treatment of hemolysis in adults with cold agglutinin disease. Reata Pharmaceuticals, Inc. (NASDAQ: RETA ), as expected, received a complete response letter for its new drug application for bardoxolone methyl as a treatment option for Alport syndrome. An Adcom that met in early December voted against recommending approval of the drug.

Organogenesis (ORGO) delivered earnings and revenue surprises of 412.50% and 3.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0% and 13.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Marinus <> has recorded the biggest intraday loss since March 2020 on Wednesday to approach a 52-week low after the clinical-stage pharma company announced delays for several…

Nervous Markets Rebound As Ukraine Tensions Fade US equity futures - which on Tuesday tumbled into a technical correction, down 10% from January''s all time highs - rebounded led by tech companies as investor fears over the standoff in Ukraine eased following the limited initial Western sanctions against Russia. As of 7:15am, eminis pared some gains but were still up 0.7% or 28 points on the day; Nasdaq futures were up 0.9% and Dow futures were up 0.54%. The VIX remained elevated, last seen around 28 after trading above 30 yesterday. Treasuries extended declines after the yield curve flattened in the Wall Street session, with the 10Y yield rising to 1.97% after tumbling as low as 1.85% on Tuesday. Crude oil fluctuated, while gold dipped as haven demand eased. The dollar slipped and cryptos reversed some of their recent losses. Susannah Streeter, senior analyst at Hargreaves Lansdown, said there were signs of bargain hunting among traders, keen to snap up shares sensitive to the situation. But she warned the geopolitical tension could still escalate, while elevated oil and gas prices were boosting inflationary risks. The volatility which has hit stocks is set to remain as traders assess this latest attempt to slow down the march toward a full invasion, said Streeter.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences

Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) expects data from the RAISE Phase 3 trial of ganaxolone in refractory status epilepticus in 2H of 2023. Earlier data from the trial was expected in 2H of 2022 . The delay is due to the impact of the COVID-19 omicron variant and an interruption of clinical supply material associated with IV ganaxolone. Marinus has temporarily paused the RAISE trial after routine Full story available on Benzinga.com

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022

Marinus Pharmaceuticals Inc (MRNS) shares closed today 10.9% lower than it did at the end of yesterday. The stock is currently up 7.3% year-to-date, up 4.5% over the past 12 months, and up 206.5% over the past five years. Today, the Dow Jones Industrial Average fell 1.0%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $13.15 and as low as $11.77 this week.Shares closed 43.3% below its 52-week high and 24.8% above its 52-week low.Trading volume this week was 6.8% higher than the 10-day average and 13.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 336.3% The company's stock price performance over the past 12 months beats the peer average by -122.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

For years, one of the most dependable sectors, especially for investors who are more conservative, was health care.

Marinus Pharmaceuticals (NASDAQ:MRNS) had its price target cut by SVB Leerink from $32.00 to $30.00 in a report issued on Monday, PriceTargets.com reports. They currently have an outperform rating on the biopharmaceutical companys stock. MRNS has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Marinus Pharmaceuticals from []

Marinus Pharmaceuticals (NASDAQ:MRNS) had its price objective lowered by equities researchers at SVB Leerink from $32.00 to $30.00 in a report released on Monday, Analyst Price Targets reports. The firm currently has an outperform rating on the biopharmaceutical companys stock. SVB Leerinks price target points to a potential upside of 167.14% from the companys current []